In 2015, as a competitive inhibitor of proteasomal DUBs (preferring USP14 over UCHL5), VLX1570 became the first case applied in phase I trials for treating multiple myeloma and solid tumors, although it has been discontinued because of dose-limiting toxicity [196]. This evidence concerns the gene USP14 and plasma cell myeloma.